Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, GEMINI Study Team, José Ramón Arribas, Andrea Antinori, Roberto Ortiz, Amanda E. Clarke, Chien Ching Hung, Jürgen K. Rockstroh, Pierre Marie Girard, Jörg Sievers*, Choy Man, Alexander Currie, Mark Underwood, Allan R. Tenorio, Keith Pappa, Brian Wynne, Anna Fettiplace, Martin Gartland, Michael AboudKimberly Smith

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

183 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science